Fontolizumab
Monoclonal antibody
NY (what is this?) (verify) Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3]
References
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
- ^ Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, et al. (February 2010). "Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory Bowel Diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334. S2CID 25337474.
- ^ Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov
- v
- t
- e
Immunosuppressive drugs / Immunosuppressants (L04)
(initiation)
Antimetabolites |
|
---|---|
Macrolides/ other IL-2 inhibitors | |
IMiDs |
(reception)
IL-1 receptor antagonists | |
---|---|
mTOR |
Antibodies |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
-cept (Fusion) |
- Avacopan
- Baricitinib
- Bimekizumab
- Blisibimod
- Briakinumab
- Brodalumab
- Canakinumab
- Crovalimab
- Danicopan]
- Deucravacitinib
- Efgartigimod alfa (+hyaluronidase)
- Etrasimod
- Filgotinib
- Fingolimod
- Guselkumab
- Iptacopan
- Itacitinib
- Ixekizumab
- Netakimab
- Olokizumab
- Ozanimod
- Peficitinib
- Pegcetacoplan
- Ponesimod
- Ravulizumab
- Risankizumab
- Ritlecitinib
- Rozanolixizumab
- Sarilumab
- Satralizumab
- Siltuximab
- Siponimod
- Sirukumab
- Spesolimab
- Sutimlimab
- Tildrakizumab
- Tofacitinib
- Upadacitinib
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e